Our Partners

Alliances formed to help build the voices of RARE

We are a community of patients, families, caregivers, researchers, practitioners, as well as industry and thought leaders, driving innovation in the way Kansas City diagnoses, treats and cares for people affected by rare diseases.

Our partners include nonprofit, healthcare, academic, research and industry organizations that believe collaboration is the key to positive change.
Children's Mercy Adele Campus

Children's Mercy Hospital

As a result of ongoing partnership with RareKC and the rare patient community, the Children’s Mercy Research Institute recently launched Genomic Answers for Kids, to build a first-of-its-kind pediatric data repository to facilitate the search for answers and novel treatments for rare pediatric genetic conditions.

KU Frontiers

Frontiers: University of Kansas Clinical and Translational Science Institute

The RareKC and Frontiers collaboration has reaped important benefits for rare disease clinical and translational research in our region. RareKC continues to support Frontiers’ as they achieve their aims and provide a lasting legacy of engagement that will accelerate new therapies, treatments and cures.

KU Med Campus

University of Kansas Medical Hospital

RareKC is working hard to establish Kansas City as a hub for rare diseases by way of the development of recognized best practices around coordinated care at the University of Kansas Medical Center and other area hospitals, which indicates how supportive the region is of rare diseases, and will continue to drive innovation in the diagnosis, care, and treatment of rare conditions.

National Partners

Life Science Supporters

Local Advocacy Organizations

Kansas City Plaza Fountain
A special thank you to our supporters in the Kansas City community
We’d love to have you engaged and supporting our efforts to better the lives of rare patients in Kansas City.
Together we can connect and inspire the rare disease community to transform the lives of those touched by rare diseases.